Alphyn is creating and leading the new class of drugs
Alphyn Biologics, Inc. (Alphyn) is creating and leading the new class of drugs known as Multi-target Therapeutics, leveraging its unique, patent-pending AB-101 platform biomaterial to develop improved therapies for diseases, in particular for those with poor or no treatment options. Alphyn’s AB-101 has over 40 bio-active compounds to target and cure diseases. AB-101, as a result of its many bioactive compounds, targets multiple diseases, and, has multiple ways to attack each disease providing Alphyn a rich and deep product pipeline.
AB-101 first product, EC1 to treat Atopic Dermatitis, solves one of the largest medical challenges to humankind – Atopic Dermatitis, including drug resistant infections. A multi-center, vehicle-controlled, randomized and double-blind Phase 2a clinical trial of AB-101a enrolling adult and pediatric patients ages 2 and up for mild to moderate AD is currently underway.
Alphyn’s management team, boards and commercial partners are highly experienced and successful in life science early stage and large companies.
Alphyn’s AB-101 started with Dr. Pekoe’s work as team lead for the development and FDA approval of Bactroban® (generic name mupirocin). In the years following, Dr Pekoe continued his interest and research in skin diseases. It was in this work that Dr. Pekoe identified and began testing AB-101, finally bringing a team together to create Alphyn Biologics for development of a new class of drugs, Multi-target Therapeutics, using AB-101 to create powerful new drugs for disease with no or less than optimal treatments.